These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30338563)

  • 1. Investigating hospital heterogeneity with a competing risks frailty model.
    Rueten-Budde AJ; Putter H; Fiocco M
    Stat Med; 2019 Jan; 38(2):269-288. PubMed ID: 30338563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporation of nested frailties into semiparametric multi-state models.
    Rotolo F; Rondeau V; Legrand C
    Stat Med; 2016 Feb; 35(4):609-21. PubMed ID: 26381148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tutorial on frailty models.
    Balan TA; Putter H
    Stat Methods Med Res; 2020 Nov; 29(11):3424-3454. PubMed ID: 32466712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frailty modeling for clustered competing risks data with missing cause of failure.
    Lee M; Ha ID; Lee Y
    Stat Methods Med Res; 2017 Feb; 26(1):356-373. PubMed ID: 25125452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of clustered competing risks data using subdistribution hazard models with multivariate frailties.
    Ha ID; Christian NJ; Jeong JH; Park J; Lee Y
    Stat Methods Med Res; 2016 Dec; 25(6):2488-2505. PubMed ID: 24619110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An issue of identifying longitudinal biomarkers for competing risks data with masked causes of failure considering frailties model.
    Ko FS
    Stat Methods Med Res; 2020 Feb; 29(2):603-616. PubMed ID: 30991892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual frailty excess hazard models in cancer epidemiology.
    Rubio FJ; Putter H; Belot A
    Stat Med; 2023 Mar; 42(7):1066-1081. PubMed ID: 36694108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixture cure models with time-varying and multilevel frailties for recurrent event data.
    Tawiah R; McLachlan GJ; Ng SK
    Stat Methods Med Res; 2020 May; 29(5):1368-1385. PubMed ID: 31293217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fitting a shared frailty illness-death model to left-truncated semi-competing risks data to examine the impact of education level on incident dementia.
    Lee C; Gilsanz P; Haneuse S
    BMC Med Res Methodol; 2021 Jan; 21(1):18. PubMed ID: 33430798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dynamic frailty model for multivariate survival data.
    Yue H; Chan KS
    Biometrics; 1997 Sep; 53(3):785-93. PubMed ID: 9333346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Semi-parametric Transformation Frailty Model for Semi-competing Risks Survival Data.
    Jiang F; Haneuse S
    Scand Stat Theory Appl; 2017 Mar; 44(1):112-129. PubMed ID: 28439147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic frailty models based on compound birth-death processes.
    Putter H; van Houwelingen HC
    Biostatistics; 2015 Jul; 16(3):550-64. PubMed ID: 25681608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A general frailty model to accommodate individual heterogeneity in the acquisition of multiple infections: An application to bivariate current status data.
    Tran TMP; Abrams S; Braekers R
    Stat Med; 2020 May; 39(12):1695-1714. PubMed ID: 32129520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interval estimation of random effects in proportional hazards models with frailties.
    Ha ID; Vaida F; Lee Y
    Stat Methods Med Res; 2016 Apr; 25(2):936-53. PubMed ID: 23361438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of statistical methods for the analysis of recurrent adverse events in the presence of non-proportional hazards and unobserved heterogeneity: a simulation study.
    Patson N; Mukaka M; Kazembe L; Eijkemans MJC; Mathanga D; Laufer MK; Chirwa T
    BMC Med Res Methodol; 2022 Jan; 22(1):24. PubMed ID: 35057743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A bivariate joint frailty model with mixture framework for survival analysis of recurrent events with dependent censoring and cure fraction.
    Tawiah R; McLachlan GJ; Ng SK
    Biometrics; 2020 Sep; 76(3):753-766. PubMed ID: 31863594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Explained variation in shared frailty models.
    Gleiss A; Gnant M; Schemper M
    Stat Med; 2018 Apr; 37(9):1482-1490. PubMed ID: 29282754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Joint frailty model for recurrent events and death in presence of cure fraction: Application to breast cancer data.
    Talebi-Ghane E; Baghestani A; Zayeri F; Rondeau V; Akhavan A
    Biom J; 2021 Apr; 63(4):725-744. PubMed ID: 33368665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Spatial Survival Model in Presence of Competing Risks for Iranian Gastrointestinal Cancer Patients.
    Hesam S; Mahmoudi M; Rahimi Foroushani A; Yaseri M; Mansournia MA
    Asian Pac J Cancer Prev; 2018 Oct; 19(10):2947-2954. PubMed ID: 30362330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of trial duration on the bias of the estimated treatment effect in clinical trials when individual heterogeneity is ignored.
    Cécilia-Joseph E; Auvert B; Broët P; Moreau T
    Biom J; 2015 May; 57(3):371-83. PubMed ID: 25597640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.